Table 3.
FLIE score and proportion of patients reporting NIDL for total, nausea domain, and vomiting domain in the mITT population
| Mean±SD or n (%) |
Differencea) (95% CI) | p-value | ||
|---|---|---|---|---|
| RAD (n=132) | PAD (n=138) | |||
| FLIE score | ||||
| Total | 115.5±17.6 | 114.8±16.7 | 0.68 (–3.43 to 4.79) | 0.745 |
| Nausea domain | 54.3±13.9 | 53.8±13.0 | 0.48 (–2.74 to 3.70) | 0.770 |
| Vomiting domain | 61.2±6.5 | 61.0±6.8 | 0.27 (–1.33 to 1.87) | 0.742 |
| NIDL | ||||
| Total ≥ 108 | 99 (75.0) | 102 (73.9) | 1.09 (–9.32 to 11.49) | 0.838 |
| Nausea domain ≥ 54 | 95 (72.0) | 91 (65.9) | 6.24 (–4.74 to 17.22) | 0.267 |
| Vomiting domain ≥ 54 | 123 (93.2) | 126 (91.3) | 1.88 (–4.49 to 8.25) | 0.565 |
FLIE score, the Functional Living Index–Emesis score; NIDL, no impact on daily life; mITT, modified intention to treatment; SD, standard deviation; RAD, ramosetron, aprepitant, and dexamethasone; PAD, palonosetron, aprepitant, and dexamethasone; CI, confidence interval.
a)
Difference was calculated as (RAD–PAD).